Advances, nuances, and potential pitfalls when exploiting the therapeutic potential of RNA interference

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 1, 2015, Pages 79-87

  Battistella, M ^a   Marsden, P A ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRAVIRSEN; PACLITAXEL; PLACEBO; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SMALL UNTRANSLATED RNA; UNTRANSLATED RNA;

AMYLOIDOSIS; ARTICLE; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG TARGETING; GENE SILENCING; HEPATITIS C; HUMAN; METABOLIC DISORDER; NEOPLASM; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA INTERFERENCE; VIRAL GENE THERAPY; VIRUS INFECTION; ANIMAL; ANOXIA; GENE THERAPY; GENETICS; MUTATION; NEOPLASMS; PHYSIOLOGICAL STRESS; PROCEDURES;

ANIMALS; ANOXIA; GENE SILENCING; GENETIC THERAPY; HUMANS; MUTATION; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; STRESS, PHYSIOLOGICAL;

EID: 84927171728     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.8     Document Type: Article

References (92)

1. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E. & Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
2. Brown, B.D. et al. Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat. Biotechnol. 25, 1457-1467 (2007).
3. Ebert, M.S. & Sharp, P.A. Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515-524 (2012).
4. Bartel, D.P. MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233 (2009).
5. Ambros, V. The functions of animal microRNAs. Nature 431, 350-355 (2004).
6. Lee, R.C., Feinbaum, R.L. & Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAswith antisense complementarity to lin-14. Cell 75, 843-854 (1993).
7. Cheloufi, S., Dos Santos, C.O., Chong, M.M. & Hannon, G.J. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 465, 584-589 (2010).
8. Hergenreider, E. et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat. Cell B ol. 14, 249-256 (2012).
9. Taverna, S. et al. Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells. Mol. Cancer 13,169 (2014).
10. Zhou, W. et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25, 501-515 (2014).
11. Huang, J.T., Wang, J., Srivastava, V., Sen, S. & Liu, S.M. MicroRNA machinery genes as novel biomarkers for cancer. Front Oncol. 4,1-9 (2014).
12. Julich, H., Willms, A., Lukacs-Kornek, V. & Kornek, M. Extracellular vesicle profiling and their use as potential disease specific bio-marker. Front Immunol. 5, 1-6 (2014).
13. Hergenreider, E. et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat. Cell B ol. 14, 249-256 (2012).
14. Cybulsky, M.I. & Marsden, P.A. Effect of disturbed blood flow on endothelial cell gene expression: a role for changes in RNA processing. Arterioscler. Thromb. Vasc. Biol. 34,1806-1808 (2014).
15. Lovren, F. et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 126, S81-90 (2012).
16. Ho, J.J.D. & Marsden, P.A. Competition and collaboration between RNA-binding proteins and microRNAs. Wileylnterdisc. Rev. RNA 5, 69-86 (2014).
17. Marsden P.A. RNA interference as potential therapy-not so fast. N. Engl. J. Med. 355, 953-954 (2006).
18. Guo, H., Ingolia, N.T., Weissman, J.S. & Bartel, D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466, 835-840 (2010).
19. Friedman, R.C., Farh, K.K., Burge, C.B. & Bartel, D.P. Most mammalian mRNAs are conserved targets of microRNAs. Genome. Res. 19, 92-105 (2009).
20. Stalder, L. et al. The rough endoplasmatic reticulum is a central nucleation site of siRNA-mediated RNA silencing. EMBO J 32,1115-1127 (2013).
21. Baccarini, A., Chauhan, H., Gardner, T.J., Jayaprakash, A.D., Sachidanandam, R. & Brown, B.D. Kinetic analysis reveals the fate of a microRNA following target regulation in mammalian cells. Curr. Biol. 21, 369-376 (2011).
22. Ho, J.J. et al. Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J. Biol. Chem. 287, 29003-29020 (2012).
23. Kozomara, A., Hunt, S., Ninova, M., Griffiths-Jones, S. & Ronshaugen, M. Target repression induced by endogenous microRNAs: large differences, small effects. PloS ONE 9, e104286 (2014).
24. Kozomara, A. & Griffiths-Jones, S. miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic. Acids Res. 42, D68-73 (2014).
25. Robb, G.B. et al. Post-transcriptional regulation of endothelial nitric oxide synthase by an overlapping antisense mRNA transcript. J. Biol. Chem. 279, 982-996 (2004).
26. Ho, J.J., Man, H.S. & Marsden, P.A. Nitric oxide signaling in hypoxia. J. Mol. Med. 90, 217-231 (2012).
27. Teichert, A.M. et al. ln vivo expression profile of an endothelial nitric oxide synthase promoter-reporter transgene. Am. J. Physiol. (Heart Circ) 278, H1352-H1361 (2000).
28. Won, D. et al. Relative reduction of endothelial nitric-oxide synthase expression and transcription in atherosclerosis-prone regions of the mouse aorta and in an in vitro model of disturbed flow. Am. J. Pathol. 171, 1691-1704 (2007).
29. Fish, J.E. et al. Hypoxia-inducible expression of a natural cis-antisense transcript inhibits endothelial nitric-oxide synthase. J. Biol. Chem. 282, 15652-15666 (2007).
30. Fish, J.E. & Marsden, P.A. Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. Cell Mol. Life Sci. 63,144-162 (2006).
31. Tai, S.C., Robb, G.B. & Marsden, P.A. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler. Thromb. Vasc. Biol. 24, 405-412 (2004).
32. Ho, J.J. et al. Active stabilization of human endothelial nitric oxide synthase mRNA by hnRNP E1 protects against antisense RNA and microRNAs. Mol. CellBiol. 33, 2029-2046 (2013).
33. Ho, J.J. & Marsden, P.A. Dicer cuts the kidney. J. Am. Soc. Nephrol. 19, 2043-2046 (2008).
34. Merritt, W.M., Bar-Eli, M. & Sood, A.K. The dicey role of Dicer: implications for RNAi therapy. Cancer Res. 70, 2571-2574 (2010).
35. Chen, S. et al. Global microRNA depletion suppresses tumor angio-genesis. Genes. Dev. 28,1054-1067 (2014).
36. Perron, M.P. & Provost, P. Protein components of the microRNA pathway and human diseases. Methods Mol. Biol. 487, 369-385 (2009).
37. Bandara, V., Michael, M.Z. & Gleadle, J.M. Hypoxia represses microRNA biogenesis proteins in breast cancer cells. BMC Cancer 14, 533 (2014).
38. Lee, N.S. et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20, 500-505 (2002).
39. Novina, C.D. et al. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8, 681-686 (2002).
40. Jacque, J.-M., Triques, K. & Stevenson, M. Modulation of HIV-1 replication by RNA interference. Nature 418, 435-438 (2002).
41. Coburn, G.A. & Cullen, B.R. Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Viro . 76, 9225-9231 (2002).
42. Kumar, P. et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134, 577-586 (2008).
43. Liu, Y.P. et al. Combinatorial RNAi against HIV-1 using extended short hairpin RNAs. Mol. Ther. 17, 1712-1723 (2009).
44. DiGiusto, D.L. et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2, 36ra43 (2010).
45. McCaffrey, A.P., Meuse, L, Karimi, M., Contag, C.H. & Kay, M.A. A potent and specific morpholino antisense inhibitor of hepatitis C translation in mice. Hepatology 38, 503-508 (2003).
46. McCaffrey, A.P. et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21, 639-644 (2003).
47. Ilves, H. et al. Inhibition of hepatitis C IRES-mediated gene expression by small hairpin RNAs in human hepatocytes and mice. Ann. NY. Acad. Sci. 1082, 52-55 (2006).
48. Khaliq, S. et al. RNAi as a new therapeutic strategy against HCV. Biotechnol. Adv. 28, 27-34 (2010).
49. Kapadia, S.B., Brideau-Andersen, A. & Chisari, F.V. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. USA 100, 2014-2018 (2003).
50. Yang, X., Haurigot, V., Zhou, S., Luo, G. & Couto, L.B. Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microrna cluster. Hepatology 52, 1877-1887 (2010).
51. Shin, D., Lee, H., Kim, S.I., Yoon, Y. & Kim, M. Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus. RNA 15, 898-910 (2009).
52. Lee, C.H., Kim, J.H. & Lee, S.W. The role of microRNAs in hepatitis C virus replication and related liver diseases. J. Microbiol. (Seoul) 52, 445-451 (2014).
53. Janssen, H.L. et al. Treatment of HCV infection by targeting micro-RNA. N. Engl. J. Med. 368,1685-1694 (2013).
54. Gebert, L.F., Rebhan, M.A., Crivelli, S.E., Denzler, R., Stoffel, M. & Hall, J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 42, 609-621 (2014).
55. van der Ree, M.H. et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res. 111c, 53-59 (2014).
56. Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369, 819-829 (2013).
57. Frank-Kamenetsky, M. et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhu-man primates. Proc. Natl. Acad. Sci. USA 105,11915-11920 (2008).
58. Zimmermann, T.S. et al. RNAi-mediated gene silencing in non-human primates. Nature 441,111-114 (2006).
59. Zhao, Z. et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514-523 (2006).
60. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M. & Burnett, J.R. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193, 445-448 (2007).
61. Fitzgerald, K. et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisinlkexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, Phase I trial. Lancet 383, 60-68 (2014).
62. Harper, S.Q. et al. RNA interference improves motor and neuropathology abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. USA of the United States of America 102, 5820-5825 (2005).
63. Ralph, G.S. et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429-433 (2005).
64. Raoul,C. et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model ofALS. Nat. Med. 11, 423-428 (2005).
65. Saito, K., Ishizuka, A., Siomi, H. & Siomi, M.C. Processing of pre-microRNAs by the Dicer-1-Loquacious complex in Drosophila cells. PLoS Biol. 3, e235 (2005).
66. Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J. & Bohn, M.C. Silencing of human a-synuclein, in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 198, 382-390 (2006).
67. Singer, O. et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 8, 1343-1349 (2005).
68. Hadaczek, P., Eberling, J.L., Pivirotto, P., Bringas, J., Forsayeth, J. & Bankiewicz, K.S. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol. Ther. 18, 1458-1461 (2010).
69. Landen, C.N. et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910-6918 (2005).
70. Phalon, C., Rao, D.D. & Nemunaitis, J. Potential use of RNA interference in cancer therapy. Expert Rev. Mol. Med. 12, e26 (2010).
71. Jackson, A.L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635-637 (2003).
72. Jackson, A.L. et al. Position-specific chemical modification of siRNAs reduces off-target transcript silencing. RNA 12,1197-1205 (2006).
73. Jackson, A.L. et al. Widespread siRNA off-target transcript silencing mediated by seed region sequence complementarity. RNA 12,1179-1187 (2006).
74. Lin, X. et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res. 33, 4527-4535 (2005).
75. Birmingham, A. et al.3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3,199-204 (2006).
76. Sledz, C.A., Holko, M., De Veer, M.J., Silverman, R.H. & Williams, B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell. Bio.l 5, 834-839 (2003).
77. Kim, D.H. & Rossi, J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8,173-184 (2007).
78. Agrawal, S. & Kandimalla, E. Role of Toll-like receptors in antisense and siRNA [corrected]. Nat. Biotechnol. 22,1533-1537 (2004).
79. Robbins, M., Judge, A. & MacLachlan, I. siRNA and innate immunity. Oligonucleotides 19, 89-102 (2009).
80. Judge, A.D., Sood, V., Shaw, J.R., Fang, D., McClintock, K. & MacLachlan, I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23, 457-462 (2005).
81. Hornung, V. et al. Sequence-specific potent induction of IFN-α,by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11, 263-270 (2005).
82. Kleinman, M.E. et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008).
83. Cho, W.G. et al. Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc. Natl. Acad. Sci. USA 106, 7137-7142 (2009).
84. Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNALshort hairpin RNA pathways. Nature 441, 537-541 (2006).
85. Davis, M.E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464,1067-1070 (2010).
86. Dassie, J.P. et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27, 839-846 (2009).
87. Zhou, J. et al. Selection, characterization and application of new RNA HIVgp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 37, 3094-3109 (2009).
88. Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717 (2005).
89. Wang, Y., Li, Z., Han, Y., Hwa Liang, L. & Ji, A. Nanoparticle-based delivery system for application of siRNA in vivo. Curr. DrugMetab 11, 182-196 (2010).
90. McNamara, J.O. et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24, 1005-1015 (2006).
91. MacDiarmid, J.A. et al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug. Nat. Bio- technol. 27, 643-651 (2009).
92. Heilbronn, R. & Weger, S. Drug Delivery. Springer, Berlin; 2010:143-170.